<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01510561</url>
  </required_header>
  <id_info>
    <org_study_id>IM-T-hPAM4-03</org_study_id>
    <nct_id>NCT01510561</nct_id>
  </id_info>
  <brief_title>A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.</brief_title>
  <official_title>A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to&#xD;
      assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and&#xD;
      effective as 3rd line treatment for patients with metastatic pancreatic cancer. Patients are&#xD;
      then followed weekly for 12 weeks and afterwards for up to 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no subjects enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (change in hematology and chemistry laboratory values from baseline)</measure>
    <time_frame>1 year</time_frame>
    <description>Acute safety will be assessed weekly for the 1st 12 weeks, and then for up to 1 year after completion of study drug treatment. Safety will be assessed by comparing baseline hematology and chemistry laboratory values with the values obtained weekly after treatment. Safety will also be assessed by the adverse events that are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosage determination</measure>
    <time_frame>2 years</time_frame>
    <description>This study is also being done to determine an acceptable 90Y-hPAM4 dose in this patient population. It is anticipated that enrollment will occur over 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 year</time_frame>
    <description>Efficacy will be assessed for at least 1 year after treatment with study drug. CT scans will be used to determine treatment response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>90Y-hPAM4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90Y-hPAM4 is administered weekly for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90Y-hPAM4 + gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y-hPAM4</intervention_name>
    <description>90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.</description>
    <arm_group_label>90Y-hPAM4</arm_group_label>
    <arm_group_label>90Y-hPAM4 + gemcitabine</arm_group_label>
    <other_name>Clivatuzumab Tetraxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y-hPAM4</intervention_name>
    <arm_group_label>90Y-hPAM4</arm_group_label>
    <arm_group_label>90Y-hPAM4 + gemcitabine</arm_group_label>
    <other_name>clivatuzumab tetraxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y-hPAM4 + gemcitabine</intervention_name>
    <arm_group_label>90Y-hPAM4 + gemcitabine</arm_group_label>
    <other_name>gemzar</other_name>
    <other_name>clivatuzumab tetraxetan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, ≥ 18 years of age, who are able to understand and give&#xD;
             written informed consent&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
          -  Stage IV (metastatic) disease, including patients who underwent surgery but had&#xD;
             incomplete resections&#xD;
&#xD;
          -  Previously treated and received two prior treatment regimens for advanced disease&#xD;
&#xD;
          -  Karnofsky performance status ≥ 60 % (Appendix A)&#xD;
&#xD;
          -  Expected survival ≥ 3 months&#xD;
&#xD;
          -  At least 4 weeks beyond major surgery, 2 weeks beyond chemotherapy, radiotherapy,&#xD;
             other experimental treatments&#xD;
&#xD;
          -  At least 2 weeks beyond corticosteroids, except low doses (i.e., 20 mg/day of&#xD;
             prednisone or equivalent) to treat nausea or other illness such as rheumatoid&#xD;
             arthritis&#xD;
&#xD;
          -  Adequate hematology without ongoing transfusional support (hemoglobin &gt; 9 g/dL, ANC &gt;&#xD;
             1,500 per mm3, platelets &gt; 100,000 per mm3)&#xD;
&#xD;
          -  Adequate renal and hepatic function (creatinine and bilirubin ≤ 1.5 X IULN, AST and&#xD;
             ALT ≤ 2.0 X IULN [5.0 X IULN if due to liver metastases])&#xD;
&#xD;
          -  Otherwise, all toxicity at study entry ≤ Grade 1 by NCI CTC v3.0 or recovered to&#xD;
             baseline or discussed with and agreed to with Immunomedics' Medical Monitor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Women of childbearing potential and fertile men unwilling to use effective&#xD;
             contraception during study until conclusion of 12-week post-treatment evaluation&#xD;
             period&#xD;
&#xD;
          -  Known metastatic disease to the central nervous system&#xD;
&#xD;
          -  Presence of bulky disease (defined as any single mass &gt; 10 cm in its greatest&#xD;
             dimension)&#xD;
&#xD;
          -  Patients with &gt; Grade 2 nausea or vomiting and/or signs of intestinal obstruction&#xD;
&#xD;
          -  Prior radiation dose &gt; 3,000 cGy to the liver, &gt; 2,000 cGy to lungs and kidneys or&#xD;
             prior external beam irradiation to a field that includes more than 30% of the red&#xD;
             marrow&#xD;
&#xD;
          -  Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are not&#xD;
             excluded, but patients with other prior malignancies must have had at least a 3-year&#xD;
             disease free interval&#xD;
&#xD;
          -  Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive&#xD;
&#xD;
          -  Known history of active coronary artery disease, unstable angina, myocardial&#xD;
             infarction, or congestive heart failure present within 6 months, or cardiac arrhythmia&#xD;
             (other than stable atrial fibrillation) requiring anti-arrhythmia therapy&#xD;
&#xD;
          -  Known history of active COPD, or other moderate-to-severe respiratory illness present&#xD;
             within 6 months&#xD;
&#xD;
          -  Known autoimmune disease or presence of autoimmune phenomena (except rheumatoid&#xD;
             arthritis requiring only low dose maintenance corticosteroids)&#xD;
&#xD;
          -  Infection requiring intravenous antibiotic use within 1 week&#xD;
&#xD;
          -  Other concurrent medical or psychiatric conditions that, in the Investigator's&#xD;
             opinion, may be likely to confound study interpretation or prevent completion of study&#xD;
             procedures and follow-up examinations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William A Wegener, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Healthcare</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services Helen Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center Univ. Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson North Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Trinity Healthcare</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell NY Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center at Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Translational Oncology Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2012</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic pancreatic adenocarcinoma</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>metastatic pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

